Business context and reporting period
This is Targacept, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2014—not a filing identified as Gyre Therapeutics, Inc. Targacept was a clinical-stage biopharmaceutical company developing neuronal nicotinic receptor (NNR) therapeutics. It reported no approved products and an accumulated deficit of $295.6 million.
Financial performance and position
| Metric | Q1 2014 | Q1 2013 / comparison |
|---|---|---|
| Operating revenue | $87,000 | $3.536 million |
| Research and development expense | $9.080 million | $8.320 million |
| General and administrative expense | $2.763 million | $3.490 million |
| Operating loss | $11.756 million | $8.274 million |
| Net loss | $14.999 million; $0.44 per share | $8.066 million; $0.24 per share |
| Cash used in operations | $14.846 million | $9.320 million |
Revenue was almost entirely absent in 2014: Q1 2013 included $3.536 million recognized after AstraZeneca terminated TC-1734 from its collaboration. Operating expenses were nearly flat overall; higher clinical-program spending outweighed lower general and administrative costs. The $3.412 million income-tax expense in Q1 2014 resulted from an examination adjustment and offsetting stock-option tax accounting, not from taxes on operating profits. Operating margin and gross margin are not meaningful indicators for this development-stage company.
At March 31, 2014, cash and cash equivalents were $45.041 million and marketable securities totaled $87.102 million, or approximately $132.1 million combined, down from $143.8 million at year-end 2013. Total assets were $134.1 million; total liabilities were $10.0 million; stockholders’ equity was $124.1 million. Debt principal outstanding was $918,000, with no remaining borrowing capacity under the equipment loan. Current assets were $98.5 million versus current liabilities of $9.9 million.
Investing activities provided $1.935 million, largely reflecting net sales/maturities of securities. Financing activities provided $3.467 million, including $3.412 million related to excess tax deductions and $273,000 in net stock issuance proceeds. Cash and cash equivalents declined by $9.444 million during the quarter.
Programs, outlook, and risks
- Management said the Phase 2b studies of TC-5214 for overactive bladder and TC-1734 for Alzheimer’s disease were planned for completion in mid-2014; it expected second-half spending on these programs to be substantially lower than first-half spending.
- Management planned to initiate an exploratory TC-6499 study for diabetic gastroparesis in mid-2014. AstraZeneca controlled substantially the development decisions for AZD1446 (TC-6683); any related milestone payments were uncertain.
- Management expected existing capital resources to fund operations through at least the end of 2015, but cautioned that operating plans and funding needs could change. Further equity financing could dilute shareholders; acceptable financing or collaboration terms might not be available.
- Key risks include clinical-trial outcomes, enrollment and timing, regulatory decisions, dependence on collaborators, intellectual-property protection, and the possibility that development will not produce marketable products. Targacept said it did not expect AstraZeneca collaboration payments to be a significant source of future funds.
- Q1 R&D expense rose $760,000, principally due to third-party clinical services, including $4.768 million for TC-5214 and $589,000 for TC-6499. Spending on TC-5619 fell after its schizophrenia study was completed in Q4 2013.
- The filing reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. It reported no material estimated exposure to a 10% interest-rate or foreign-exchange movement.
Important facts for investors to verify
- Confirm issuer identity: the supplied filing names Targacept, Inc., while the request metadata names Gyre Therapeutics, Inc.
- Check subsequent disclosures for actual completion and results of the TC-5214 and TC-1734 trials and whether the stated TC-6499 study began as planned.
- Assess the assumptions underlying the stated cash runway through at least year-end 2015, including development spending and potential financing needs.
- Verify AstraZeneca’s AZD1446 development plans and any milestone eligibility; the filing describes potential payments but emphasizes their uncertainty.
- Review the full risk-factor disclosures and tax-asset limitations, including potential ownership-change restrictions on net operating loss and credit carryforwards.